Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Home
/
med-marvels
/
details

Defeating Cancer Together: Immuneel’s CAR T-Cell Therapy Breakthrough in India

NextEdge Admin

25 Mar 2024

3 min 42 sec

A twenty-two-year-old patient’s love for the wind on his face as he runs was abruptly halted when he was diagnosed with Acute Lymphoblastic Leukemia (ALL) a year ago. However, a novel therapy at a government hospital has brought him back to life, making him the first clinical trial patient in India to receive CAR T-cell therapy for ALL.

Reflecting on his decision to participate in the trial, the patient recalls the desperation he felt as chemotherapy failed to improve his condition. “I had lost 30 kg, my hair, and my energy. The days of the trial were tense, but my doctors were supportive,” he recounts.

The therapy, developed by Immuneel, genetically reprograms a patient’s immune system to target and destroy cancer cells. Prof Pankaj Malhotra of PGIMER explains that the patient is now cancer-free and off therapy, back to his college routine with just regular follow-ups advised.

The innovative therapy modifies T-cells using an inactivated HIV virus to empower them to fight cancer. Dr. Sidharth Mukherjee, co-founder of Immuneel, emphasized the safety of the modified virus during the launch of the trials.

The patient’s battle with cancer began with persistent fever and weakness, leading to his diagnosis in Saharanpur. Despite being a fitness enthusiast, he found himself facing the harsh reality of blood cancer. His journey at PGIMER involved chemotherapy, but when conventional treatment failed, he became a candidate for the CAR T-cell therapy trial.

Dr. Charanpreet Singh highlights the patient’s positive response to the therapy, evident in clean PET scan results and subsequent reviews. The patient expresses his joy at being given a new lease of life, though he remains mindful of the potential risks associated with the therapy.

The doctors at PGIMER are closely monitoring the patient and other trial participants to ensure continued success, which is crucial for the therapy’s approval. Once approved, the hospital aims to offer the therapy at a fraction of the cost charged abroad, making it more accessible to patients like the patient.

As for the patient, he has regained his original weight, hair, and zest for life. Determined to reclaim the year he lost to treatment, he plans to complete his graduation and pursue a career in finance, feeling like himself once more.